HighPoint Advisor Group’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $339K | Sell |
1,600
-59
| -4% | -$11.6K | 0.01% | 546 |
|
|
2026
Q1 | $325K | Sell |
1,659
-7,232
| -81% | -$1.41M | 0.01% | 515 |
|
|
2025
Q4 | $1.54M | Buy |
8,891
+1,926
| +28% | +$351K | 0.03% | 365 |
|
|
2025
Q3 | $1.33M | Buy |
6,965
+618
| +10% | +$110K | 0.06% | 217 |
|
|
2025
Q2 | $1.14M | Buy |
6,347
+186
| +3% | +$32.3K | 0.06% | 228 |
|
|
2025
Q1 | $1.1M | Buy |
6,161
+306
| +5% | +$50.3K | 0.06% | 225 |
|
|
2024
Q4 | $977K | Buy |
5,855
+456
| +8% | +$70.9K | 0.05% | 244 |
|
|
2024
Q3 | $838K | Buy |
5,399
+394
| +8% | +$58.8K | 0.05% | 264 |
|
|
2024
Q2 | $715K | Buy |
5,005
+69
| +1% | +$9.45K | 0.04% | 285 |
|
|
2024
Q1 | $695K | Buy |
4,936
+409
| +9% | +$53.1K | 0.05% | 280 |
|
|
2023
Q4 | $585K | Buy |
+4,527
| New | +$595K | 0.04% | 323 |
|
|
2022
Q2 | $498K | Buy |
+3,667
| New | +$500K | 0.05% | 288 |
|
|
2021
Q3 | $481K | Buy |
3,308
+71
| +2% | +$10.4K | 0.05% | 319 |
|
|
2021
Q2 | $427K | Buy |
3,237
+236
| +8% | +$30.9K | 0.04% | 331 |
|
|
2021
Q1 | $380K | Buy |
3,001
+7
| +0.2% | +$863 | 0.04% | 324 |
|
|
2020
Q4 | $365K | Buy |
2,994
+35
| +1% | +$4.27K | 0.04% | 317 |
|
|
2020
Q3 | $379K | Buy |
2,959
+17
| +0.6% | +$2.01K | 0.07% | 229 |
|
|
2020
Q2 | $336K | Sell |
2,942
-518
| -15% | -$54.9K | 0.07% | 219 |
|
|
2020
Q1 | $368K | Buy |
3,460
+129
| +4% | +$13.4K | 0.09% | 191 |
|
|
2019
Q4 | $357K | Buy |
3,331
+143
| +4% | +$14.9K | 0.07% | 230 |
|
|
2019
Q3 | $323K | Buy |
3,188
+123
| +4% | +$12.6K | 0.07% | 234 |
|
|
2019
Q2 | $300K | Sell |
3,065
-41
| -1% | -$3.94K | 0.07% | 245 |
|
|
2019
Q1 | $303K | Buy |
3,106
+379
| +14% | +$32.8K | 0.07% | 239 |
|
|
2018
Q4 | $240K | Buy |
2,727
+734
| +37% | +$68.8K | 0.06% | 268 |
|
|
2018
Q3 | $202K | Buy |
1,993
+6
| +0.3% | +$658 | 0.06% | 298 |
|
|
2018
Q2 | $218K | Buy |
1,987
+6
| +0.3% | +$625 | 0.06% | 294 |
|
|
2018
Q1 | $217K | Buy |
+1,981
| New | +$203K | 0.06% | 295 |
|
|
2017
Q4 | – | Sell |
-2,330
| Closed | -$218K | – | 303 |
|
|
2017
Q3 | $218K | Sell |
2,330
-9,206
| -80% | -$977K | 0.07% | 248 |
|
|
2017
Q2 | $607K | Hold |
11,536
| – | – | 0.2% | 138 |
|
|
2017
Q1 | $607K | Buy |
11,536
+3,622
| +46% | +$345K | 0.2% | 138 |
|
|
2016
Q4 | $779K | Buy |
7,914
+42
| +0.5% | +$3.62K | 0.25% | 105 |
|
|
2016
Q3 | $675K | Sell |
7,872
-586
| -7% | -$49.2K | 0.24% | 104 |
|
|
2016
Q2 | $723K | Buy |
+8,458
| New | +$644K | 0.25% | 105 |
|
Other funds holding DGX
EIG
HighPoint Advisor Group's DGX Position: Q2 2026 in Review
HighPoint Advisor Group reduced its Quest Diagnostics (DGX) stake by 3.6% in Q2 2026, selling an estimated $11.6K and leaving 1,600 shares worth $339K. The position accounts for 0.01% of the portfolio, ranked #546.
HighPoint Advisor Group first reported a position in DGX in Q2 2016 and has held it in 33 quarters since. The position peaked at $1.54M in Q4 2025. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.
- HighPoint Advisor Group held 1,600 shares of Quest Diagnostics worth $339K as of Q2 2026.
- HighPoint Advisor Group sold 59 Quest Diagnostics shares in Q2 2026, an estimated $11.6K.
- Quest Diagnostics made up 0.01% of HighPoint Advisor Group's portfolio in Q2 2026, its #546 holding.
- HighPoint Advisor Group first reported a position in Quest Diagnostics in Q2 2016 and has held it in 33 quarters since.
- HighPoint Advisor Group's Quest Diagnostics position peaked at $1.54M in Q4 2025.
- 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.
Based on HighPoint Advisor Group's 13F filing for Q2 2026, filed 5 Aug 2026.